Sucraid® is an enzyme replacement therapy that contains sacrosidase as a substitute for sucrase, which is one of the enzymes that is defective in individuals who have Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase facilitates the breakdown of sucrose (sugar) into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® has been documented to help relieve the gastrointestinal symptoms associated with CSID, and as a result, help affected individuals consume a more normal diet that includes sucrose-containing foods.
Congenital Sucrase-Isomaltase Deficiency (CSID), also known as Genetic Sucrase-Isomaltase Deficiency (GSID), is an autosomal recessive disorder that causes a deficiency in sucrase-isomaltase (SI), the enzyme responsible for the metabolism of sucrose and other sugars found in starch, and the subsequent absorption of their metabolites, glucose and fructose.
CSID is largely a clinical diagnosis, but there are diagnostic tools to assess sucrase enzyme activity.
Sucraid® is only available through an exclusive specialty pharmacy provider that ships the therapy directly to the patient’s home or physician’s office.
Download the Sucraid 4-Day Trial Rx form
and see if Sucraid® is right for your patients.
*Patients who took Sucraid® with each meal were considered asymptomatic if reported no GI symptoms for at least 7 of the 10 study days.
The proper Sucraid® dose depends on the patient’s body weight.
